Abstracts tagged "Disease Activity"

Abstract Number: 0459 • ACR Convergence 2020
Autologous Hematopoietic Stem Cell Transplantation for Behçet’s Disease: A Retrospective Survey of Patients Treated in Europe, on the Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Bone Marrow Transplantation
Mathieu Puyade¹, Patel Amit², Yeong Jer Lim³, Norbert Blank⁴, Manuela Badoglio⁵, Francesca Gualandi⁶, David D Ma⁷, Raffaella Greco⁸, Natalia Maximova⁹, Tobias Alexander¹⁰ and John A Snowden¹¹, ¹Service de Médecine Interne et Maladies Infectieuses ,CIC-1402 Centre Hospitalier Universitaire de Poitiers, Poitiers, France, ²The Christie NHS Foundation Trust, Manchester, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom, ⁴Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ⁵EBMT ADWP Office, Paris, France, ⁶U.O. EMATOLOGIA Centro Trapianti Midollo - OSPEDALE POLICLINICO SAN MARTINO, GENOVA, Italy, ⁷Department of Haematology and BM Transplantation, St Vincent’s Hospital Sydney and St Vincent’s Clinical School, Faculty of Medicine, Sidney, New South Wales, Australia, ⁸Ematologia Trapianto Midollo San Raffaele, Milano, Italy, ⁹Institute for Maternal and Child Health – IRCCS Burlo Garofolo, Trieste, Italy, ¹⁰Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ¹¹Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
Background/Purpose: Behçet’s Disease (BD) is a rare autoimmune disease mostly presenting with recurrent oral and genital aphtosis, ulcers, and uveitis. Rare patients are refractory to…
Abstract Number: 0799 • ACR Convergence 2020
Effectiveness of Electronic Drug Monitoring Feedback in Order to Increase Adherence in RA Patients Starting with a Biological DMARD
Renske Hebing¹, Wouter Bos¹, Mike Nurmohamed² and Bart van den Bemt³, ¹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Medication non-adherence in rheumatoid arthritis (RA) is associated with disease flares, increased disability and increased costs. Electronic Monitoring Feedback (EMF) to improve adherence has…
Abstract Number: 0905 • ACR Convergence 2020
Probability of Achieving Low Disease Activity or Remission with Apremilast Treatment Among DMARD-Naive Subjects with Active Psoriatic Arthritis
Philip Mease¹, Arthur Kavanaugh², Alexis Ogdie³, Alvin Wells⁴, Martin Bergman⁵, Dafna Gladman⁶, Frank Behrens⁷, Sven Richter⁸, Michele Brunori⁹, Lichen Teng⁸, Benoit Guerette⁸ and Josef Smolen¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²UC San Diego Health System, San Diego, CA, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Aurora Rheumatology and Immunotherapy Center, Franklin, ⁵Drexel University College of Medicine, Philadelphia, PA, ⁶Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁷CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ⁸Amgen Inc., Thousand Oaks, ⁹Amgen Europe GmbH, Rotkreuz, Switzerland, ¹⁰Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: Apremilast (APR) is associated with comparable ACR response rates in DMARD-naive vs DMARD-experienced patients (pts) with PsA (Wells AF, et al. Rheumatology. 2018;57:1253-63; Kavanaugh…
Abstract Number: 1184 • ACR Convergence 2020
In a Prospective RA Cohort, Higher Baseline Disease Activity Is an Independent Predictor of Decline in Left Ventricular Diastolic Function
Elizabeth Park¹, Kazato Ito², Christopher Depender¹, Jon Giles¹ and Joan Bathon¹, ¹Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ²Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY
Background/Purpose: Rheumatoid Arthritis (RA) patients are at nearly 50% increased risk of heart failure (HF) compared to non-RA patients, despite adjusting for the presence of…
Abstract Number: 1319 • ACR Convergence 2020
Disease Activity and Mental Health of as Patients: A Cross-section Study with Self-assessments Based on Smart System of Disease Management (SSDM) Mobile Tools
Hui Song¹, Hua Wei², Miaojia Zhang³, Lijun Wu⁴, Zhenbiao Wu⁵, Aichun Chu⁶, Bei Wang⁷, Wenqiang Fan⁸, Xiaohan Wang⁹, Xiaoqi Chen¹⁰, Henglian Wu¹¹, Wenyu Zhou¹², Fei Xiao¹³, Hui Xiao¹⁴, Yuhua Jia¹³, Bing Wu¹³ and Jing Lu¹⁵, ¹Beijing Jishuitan Hospital, Beijing, China (People's Republic), ²Northern Jiangsu People's Hospital, Yangzhou, China (People's Republic), ³Jiangsu Province Hospital, The first affiliated hospital of Nanjing medical university, Nanjing, China (People's Republic), ⁴People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China (People's Republic), ⁵The First Affiliated Hospital of The Air Force Medical University, Xi＇an, Shanxi, China (People's Republic), ⁶Remin Hospital of Wuhan University Hubei General Hospital, Wuhan, China (People's Republic), ⁷Beijing Hospital of Traditional Chinese Medicine, Beijing, China (People's Republic), ⁸Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁹Anyang district hospital, Anyang, Henan, China (People's Republic), ¹⁰Zhongnan Hospital of Wuhan University, Wuhan, China (People's Republic), ¹¹Dongguan Donghua Hospital, Dongguan, Guangdong, China (People's Republic), ¹²Wuhan No. 4 Hospital, Wuhan, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁴Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁵First Affiliated Hospital of China Medical University, Shenyang, China (People's Republic)
Background/Purpose: WHO survey showed that the prevalence of anxiety and depression in Chinese population and Chinese patients with chronic diseases were between 3.1% - 4.2%…
Abstract Number: 1632 • ACR Convergence 2020
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Joerg Henes¹, Norbert Blank², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Markus Hufnagel⁶, Tilmann Kallinich⁷, Birgit Kortus-Goetze⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, ⁷Charite, Berlin, Germany, ⁸Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully treated with the anti-IL-1ß inhibitor canakinumab.…
Abstract Number: 1789 • ACR Convergence 2020
Time to Renal Insufficiency Based on 25(OH)-Vitamin D Levels
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: Vitamin D is correctly classified as a sterol-hormone rather than a vitamin (Semin Nephrol 1986;6:4-20). It has multiple immunomodulatory effects, as well as cardiovascular…
Abstract Number: 1891 • ACR Convergence 2020
Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study
Ashit Syngle¹, Nidhi Garg² and Kanchan Chauhan¹, ¹Healing Touch City Clinic, Chandigarh, Chandigarh, India, ²Chitkara University, Rajpura, Punjab, India
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…
Abstract Number: 0157 • ACR Convergence 2020
Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?
Cristina Valero¹, Noelia Garcia¹, Juan Pablo Baldivieso², Ana Ortiz³, Sebastian Rodriguez² and Isidoro González-Álvaro³, ¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²Hospital de La Princesa, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: In recent years there is increasing evidence of the relevance of including the assessment of the different aspects of rheumatoid arthritis (RA) from the…
Abstract Number: 0302 • ACR Convergence 2020
Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Kieran Manion¹, Dennisse Bonilla², Dafna Gladman¹, Murray Urowitz³, Zahi Touma⁴ and Joan Wither², ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: In SLE, periods of relative quiescence are punctuated by flares in disease activity that can lead to extensive tissue damage and morbidity. Existing studies…
Abstract Number: 0479 • ACR Convergence 2020
Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis
Marloes Verstappen¹, Ellis Niemantsverdriet², Xanthe Matthijssen², Saskia le Cessie² and Annette van der Helm - van Mil³, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Sustained DMARD-free remission (SDFR) is increasingly achievable. The pathogenesis underlying SDFR-development is unknown and patient-characteristics at diagnosis poorly explain whether SDFR will be achieved.…
Abstract Number: 0802 • ACR Convergence 2020
Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Yoshiya Tanaka¹, Hisashi Yamanaka², Leslie Harrold³, Tin-chi Lin³, Ekta Agarwal⁴, Jose L Rivas⁵, Naonobu Sugiyama⁶, Jeffrey Greenberg⁷ and Mitsumasa Kishimoto⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ²Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ³Corrona, LLC, Waltham, MA, ⁴Pfizer, Inc., Princeton Jct, NJ, ⁵Pfizer SLU, Madrid, Spain, ⁶Pfizer Japan Inc, Tokyo, Japan, ⁷Corrona, LLC and NYU School of Medicine, Waltham, MA, ⁸Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: There are several conventional synthetic, targeted synthetic and biological disease-modifying anti-rheumatic medications (DMARDs) approved for the treatment of rheumatoid arthritis (RA) in Japan. Little…
Abstract Number: 0907 • ACR Convergence 2020
Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
Laura Coates¹, Dafna Gladman², Filip Van den Bosch³, Philip Helliwell⁴, Anna Rychlewska-Hańczewska⁵, Mykola Stanislavchuk⁶, Leen Gilles⁷, Lien Gheyle⁷, Ke Liu⁸, Mona Trivedi⁸, Muhsen Alani⁹, Robin Besuyen¹⁰ and Philip Mease¹¹, ¹University of Oxford, Oxford, United Kingdom, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Ghent University Hospital, Ghent, Belgium, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Ai Centrum Medyczne, Poznań, Poland, ⁶National Pirogov Memorial Medical University, Vinnytsya, Ukraine, ⁷Galapagos NV, Mechelen, Belgium, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc. and University of Washington, Foster City, CA, ¹⁰Galapagos BV, Leiden, Netherlands, ¹¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P,…
Abstract Number: 1185 • ACR Convergence 2020
Performance of the MBDA-based CVD Risk Score in RA Patient Groups of Clinical Interest
Jeffrey R Curtis¹, Fenglong Xie², Cynthia Crowson³, Eric Sasso⁴, Elena Hitraya⁴, Cheryl Chin⁵, Richard Bamford⁵, Rotem Ben-Shachar⁵, Alexander Gutin⁵, Darl Flake⁵, Brent Mabey⁵ and Jerry Lanchbury⁵, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁴Myriad Autoimmune, South San Francisco, CA, ⁵Myriad Genetics, Inc., Salt Lake City, UT
Background/Purpose: A novel risk prediction score combines serum biomarkers from the multi-biomarker disease activity (MBDA) test with clinical information to predict 3-year risk for a…
Abstract Number: 1321 • ACR Convergence 2020
Central Sensitization, Disease Perception and Obesity Should Be Taken into Account When Interpreting Disease Activity in Patients with Axial Spondyloarthritis
Stan Kieskamp¹, Davy Paap², Marllies Carbo¹, Freke Wink³, Reinhard Bos⁴, Hendrika Bootsma¹, Suzanne Arends⁵ and Anneke Spoorenberg⁵, ¹University Medical Centre Groningen, Groningen, Netherlands, ², Department of Rehabilitation Medicine, University of Medical Centre Groningen, Groningen, Netherlands, ³Medical Centre Leeuwarden, Leeuwarden, Netherlands, ⁴Medical Centre Leeuwarden, Leeuwarden, ⁵University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands
Background/Purpose: Up to 40% of ankylosing spondylitis patients report persistently high pain scores of >4 (scale of 0-10) even after responding to long-term TNF-α blocking…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].